Supernus Pharmaceuticals Inc. (NASDAQ:SUPN)’s share price fell 1.4% during trading on Thursday . The stock traded as low as $21.51 and last traded at $21.55, with a volume of 235,874 shares changing hands. The stock had previously closed at $21.86.

Several research firms have recently commented on SUPN. Zacks Investment Research cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. Jefferies Group reiterated a “buy” rating and set a $28.00 target price (up from $23.00) on shares of Supernus Pharmaceuticals in a research note on Thursday, August 4th. Northland Securities cut Supernus Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $24.00 target price for the company. in a research note on Monday, July 18th. Finally, Piper Jaffray Cos. cut Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and set a $23.00 target price for the company. in a research note on Monday, July 18th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $24.50.

The stock has a 50-day moving average of $22.00 and a 200 day moving average of $17.88. The stock has a market cap of $1.06 billion and a PE ratio of 43.57.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings results on Tuesday, August 2nd. The specialty pharmaceutical company reported $0.18 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.13 by $0.05. During the same period last year, the business earned $0.03 earnings per share. The firm had revenue of $50.40 million for the quarter, compared to analysts’ expectations of $49.67 million. The firm’s revenue for the quarter was up 43.6% on a year-over-year basis. On average, equities analysts predict that Supernus Pharmaceuticals Inc. will post $0.68 EPS for the current fiscal year.

In related news, CFO Gregory S. Patrick sold 3,395 shares of the firm’s stock in a transaction that occurred on Thursday, July 14th. The stock was sold at an average price of $22.00, for a total value of $74,690.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

A hedge fund recently raised its stake in Supernus Pharmaceuticals stock. New York State Common Retirement Fund increased its position in shares of Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) by 3.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 205,981 shares of the specialty pharmaceutical company’s stock after buying an additional 7,299 shares during the period. New York State Common Retirement Fund owned 0.42% of Supernus Pharmaceuticals worth $2,768,000 as of its most recent filing with the SEC.

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.